Two new studies find Bayer's contraceptives Yaz and Yasmin have an increased risk of blood clots
According to two new studies published in the on-line edition of the British Medical Journal, German drugs and chemicals major Bayer's (BAY: DE) contraceptive pills Yaz (3mg drospirenone/0.02mg ethinyl estradiol) and Yasmin, (3mg drospirenone/0.03mg ethinyl estradiol) carry up to triple the risk of venous thromboembolism (blood clots) over traditional pills containing the progestin levonorgestrel (LNG).
The findings of the new studies provide additional evidence that the older oral contraceptives "appear to be a safer choice with regard to venous thromboembolism than preparations containing drospirenone," says Susan Jick of Boston University's School of Medicine, who led the research team.
Study results
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze